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ABSTRACT: A structure-activity relationship (SAR) for the oxadiazole class of antibacterials was evaluated by syntheses of 72 
analogs and determination of the minimal-inhibitory concentrations (MICs) against the ESKAPE panel of bacteria. Selected 
compounds were further evaluated for in vitro toxicity, plasma protein binding, pharmacokinetics (PK), and a mouse model of 
methicillin-resistant Staphylococcus aureus (MRSA) infection.  Oxadiazole 72c showed potent in vitro antibacterial activity, exhibits 
low clearance, a high volume of distribution, 41% oral bioavailability, and shows efficacy in mouse models of MRSA infection. 
Antibiotics have been called miracle drugs. Not only have 
they saved millions of lives in treatment of infections, they have 
also made possible other medical interventions such as surgery, 
dialysis, and organ transplantation. The availability of 
antibiotics has contributed to the increase in life expectancy in 
the United States from 59.7 years in 1930 to 78.8 years in 2010.1  
Notwithstanding, emergence of resistance to any antibiotic is 
inevitable, threatening viability of any given class of such 
agents. Among Gram-positive bacteria, resistant 
Staphylococcus aureus and Enterococci pose the biggest 
threat.2 S. aureus is a leading cause of health-related infections. 
Every year in the United States more than 80,000 severe 
methicillin-resistant S. aureus (MRSA) infections occur, 
resulting in 11,285 annual deaths.3 Enterococci cause 
infections, including endocarditis, urinary-tract infections, and 
wound infections. Over 66,000 Enterococcus infections are 
reported every year in the United States, of which 20,000 are 
vancomycin-resistant Enterococcus (VRE), resulting in 1,300 
deaths.3 The limited pipeline of new antibiotics has exacerbated 
the antibiotic-resistance crisis.
The oxadiazoles are a newly discovered class of non-β-lactam 
antibiotics targeting cell-wall biosynthesis.4 These antibiotics 
show potent bactericidal activity against difficult-to-treat 
Gram-positive bacteria, including MRSA and VRE. They do 
not have Gram-negative antibacterial activity. Our initial 
studies into this class of antibiotics produced lead compounds 
1–3, of which 2 and 3 exhibit 100% oral bioavailability and in 
vivo efficacy.4 Further studies on compound 2 suggested 
inhibition of the penicillin-binding proteins (PBPs) of S. aureus, 
which are responsible for bacterial cell-wall biosynthesis.4
With a view to explore the structural space of this class of 
antibiotics, we recently reported a structure-activity 
relationship (SAR) of the oxadiazoles against S. aureus5 with a 
focus on modifications in ring A. We found that 4-phenol, 4-
chloropyrazole, or 5-indole substitutions were generally 
favored at this position (1, 2, and 4–8; Figure 1). These 
compounds exhibit minimal-inhibitory concentration (MIC) 
values against S. aureus ranging from 0.5 to 4 g/mL. 
Furthermore, antibiotic 8 gave excellent efficacy in MRSA-
infected mice comparable to results obtained with linezolid, the 
gold standard, and exhibited oral bioavailability and low 
toxicity.5-6
We report herein the synthesis and SAR results against S. 
aureus of 72 synthetic oxadiazoles with modifications in ring D 
(see Figure 1 for ring designations). To enable a comparison to 
our previously reported active compounds, we have limited our 
discussion in this report to compounds with the aforementioned 
ring A modifications. The SAR was established by initial 
screening of the synthetic derivatives against the ESKAPE 
panel of bacteria. This panel is comprised of Enterococcus 
faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa, and 
Enterobacter sp., and Escherichia coli. These bacteria account 
for the majority of problematic human infections.7 Selected 
compounds were further evaluated for in vitro toxicity, plasma 
protein binding, pharmacokinetics (PK), and in mouse models 














1 R1 = OH, R2 = H
2 R1 = OH, R2 = CF3
3 R1 = NH2, R2 = CF3
4 R = H
5 R = CF3
6 R = F
7 R = H
8 R = CF3
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C D
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12: X = 4-F
13: X = 4-I
14: X = 3-F, 4-F
X
Syntheses of N'-Hydroxybenzimidamides: ZH2N
N
HO
55  58 d






































16: R' = 3-F, 4-F
17: R' = 3-Cl, 4-Cl
18: R' = 4-I
19: R' = 4-OCF3
20: R' = 4-Br
21: R' = 3-I
22: R' = 2-I












55: R = Bn












44: R' = NBoc
45: R' = NCH3
R'
HO
41: R' = NBoc
42: R' = O










39: R' = NBoc
40: R' = CHNHBoc
38
24: R' = 4-COCF3
25: R' = 3-Cl, 4-F
26: R' = 4-F
27: R' = 3-Br
28: R' = 4-SO2CH3
29: R' = 4-COCH3
30: R' = 2-Br, 4-F
31: R' = 2-Br, 4-OCH3
32: R' = 2-Br, 4-OCF3
33: R' = 2-Br
34: R' = 2-Br, 4-CF3





Acid Derivatives & Halides
57: R = t-Bu




Figure 2. General synthetic routes to access the 1,2,4-oxadiazoles, and the starting materials used for variations within ring D. aNucleophilic 
substitution: NaH/K2CO3, DMSO/DMF, 60 – 100 ºC, overnight; bUllmann coupling: CuI, Cs2CO3, N,N-dimethylglycine·HCl, 1,4-dioxane, 
90 ºC, 2 – 5 h ; cAcylation: anhydrous pyridine, 0 ºC to rt, 4 – 6 h; dOutliers like dibenzo[b,d]furan and dibenzo[b,e][1,4]dioxine are not 
listed for simplicity of the graph. Compounds 55 – 58 are 4-cyanophenyl ethers purchased commercially; eAdditional modifications are listed 
in Supporting Information.
Figure 3. Antibacterial activities of the synthetic 1,2,4-oxadiazole derivatives with modifications of ring D. The MIC values (in μg/mL) 
measured for S. aureus ATCC 29213, with MIC of active compounds  denoted in blue (MIC ≤ 8 μg/mL) and inactive ones in red (MIC > 8 
μg/mL).
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The general synthetic routes to the oxadiazoles have been described 
previously.4-5 The same approach was used to access the analogs 
reported herein, except our focus was on modification of ring D, 
which necessitated diversification of the structures at the stage of 
the diphenyl ether construction. This was achieved either by direct 
nucleophilic substitution and Ullmann coupling reactions of nitriles 
12–14 or direct nucleophilic substitution and acylation of 4-
hydroxybenzonitrile 15 (Figure 2). In many cases, ring D variations 
could be introduced by using commercially available substituted 
phenols (16–48), carboxylic acid derivatives (50, 51, 53 and 54) or 
halides (49 and 52). The substituents of several of these analogs 
could be used as synthetic handles for further elaboration, the 
reactions of which are described in the Supporting Information. In 
some cases where ring D was replaced by non-annular substituents, 
the requisite ethers were purchased (55–58).
We established the SAR for the oxadiazoles by screening 
them for antibacterial activity against the aforementioned 
ESKAPE panel of bacteria. The analogs reported herein show 
activity against Gram-positive bacteria. We specifically 
focused our attention on the analogs that exhibited activity 
against S. aureus (Figure 3). 
In general, hydrophobic substituents, and especially halogens, 
were well-tolerated in ring D. Addition of an extra fluorine 
(59b) or chlorine (69b) at the 3-position retained activity in the 
4-chloropyrazole series, as did substitution by two chlorines at 
these same positions (60b). Replacement of the fluorine by an 
iodine, either at position 4 (61b, 75a), position 3 (74a), or 
position 2 (67a) also retained activity overall. The same trend 
was observed with introduction of a bromine atom at position 4 
(63a) or position 3 (73a). Introduction of a trifluoromethoxy or 
methoxy group at position 4 of the ring (62a, 68a) also retained 
activity, as did the presence of a 3-trifluoromethyl ketone 
substituent (70a). An azide group at any position of the ring also 
maintained a favorable MIC against S. aureus (64a, 65a, 66a). 
Interestingly, a benzylic bromide at position 2 (76a) or position 
3 (77a) of the ring did not result in a noticeable increase in MIC, 
but introduction of this substituent at position 4 (89a) 
completely abolished activity.
We also explored the effect of tethering rings C and D at their 
respective 2-positions to form a dibenzofuran, and we found 
that the resulting compounds where ring A was a phenol were 
inactive when ring D was unsubstituted (93a) or substituted 
with a 4-trifluoromethyl group (94a), 4-fluoro (90a), 4-
methoxy (91a), or 4-trifluoromethoxy (92b). Likewise, 
expanding the furan portion with a heteroatom to form 
dibenzodioxine 105a resulted in loss of activity.
Replacing ring D with linear alkyl substituents resulted in 
only one active compound, the trifluoromethoxy derivative 78a, 
which contains a phenol for ring A. However, changing ring A 
to a 4-chloropyrazole (78b) or an indole (78c) resulted in loss 
of activity. The reasons for this are not clear at present. Other 
alkyl substituents introduced as surrogates for ring D, such as 
methyl (96a, 96b) and tert-butyl (97a) gave compounds with 
poor activity, as did sulfonates (98a, 99a), alkylcarbamates 
(100a) and amines (101a), and amides (102a, 103a, 104a).
We observed that introducing partially or fully saturated 
systems at ring D gave compounds with good activity in a few 
cases. Introduction of a nitrogen atom to give 3-pyrrolidines 
113a and 114b, or of an oxygen atom to give 3-tetrahydrofuran 
115a, decreased or abolished the activity. As a general trend, 
introduction of hydrogen-bond-donating substituents at ring D 
resulted in compounds with decreased antimicrobial activity 
against S. aureus. Thus, the 4-phenol derivative 79a was only 
modestly active (MIC = 16 g/mL), and 2-benzyl alcohol 88a 
exhibited no activity. Similarly, benzoic acid derivatives 80a, 
81a, and 82a were either poorly active or inactive, and 2-
carboxamide 83a and 2-aniline 84a were inactive. Introduction 
of polar substituents onto an aliphatic system also resulted in 
compounds with no activity, as observed with 4-
aminocyclohexane derivatives 111a, and 112a. Electron-
withdrawing substituents introduced onto ring D also resulted 
in compounds with no activity, as evidenced by 4-benzonitriles 
85a and 85b, as well as 4-methylsulfonate 86b and 4-acetate 
87b. One exception is 2-nitro derivative 71a, which had an MIC 
of 4 g/mL against S aureus.
Replacement of the phenyl ring at position D with 
heteroaromatic systems was also detrimental to activity. Thus, 
benzothiazole derivative 106b was modestly active (MIC = 16 
g/mL), while pyridine derivative 107a was inactive (MIC 
>128 g/mL). We observed a similar trend with heteroaliphatic 
ring systems, such as 4-piperidines (108a, 108b, 109b, 110a), 
3-piperidines (117a, 117b, 118a, 118b), 3-azetidines (119a), as 
well as the pyrrolidines and tetrahydrofuran discussed above. 
Finally, we introduced more complex aliphatic amine-
containing ring systems, giving quinuclidine derivatives 120a 
and 120b and tropine derivatives 121a and 121b, however, 
these exhibited poor activity against S. aureus (MIC ≥32 
g/mL).
Compounds 59b, 60b, 61b, 62a, 69b, 78a, and 72c were 
selected and further evaluated for in vitro toxicity using the 
XTT assay with HepG2 cells and hemolysis of red blood cells 
(Table 1). Compound 78a, in which the ring D was replaced 
with trifluoromethoxy caused 16% hemolysis at a concentration 
of 64 µg/mL; no further studies were done with this compound. 
Plasma protein binding was between 90% to 99%. Although 
high, it is within the range for 43% of the 1500 most frequently 
prescribed drugs,8 including many antibiotics on the market 
such as daptomycin, oxacillin, teicoplanin, rifampicin, and 
clindamycin.9-12 Compounds 59b, 60b, 61b, 62a, and 69b 
showed >1% hemolysis or < 35 for the ratio of XTT/MIC and 
were not studied further. 











8a 2 98.2  3.2 75.7  7.3 <1
59b 0.5 98.9  1.6 17.7  1.0 1.3
60b 1 97.8  0.3 17.2  1.0 1.8
61b 1 90.5  0.3 30.7  0.8 3.1
62a 2 99.8  0.1 16.9  0.9 2.1
69b 2 91.2  0.6 21.0  0.9 2.9
78a 1 ND 84.9  0.9 16
72c 1 98.8  0.7 37.0  0.9 <1
aData from Spink et al., reproduced for comparison
Compound 72c was evaluated in a broader panel of Gram-
positive bacteria and compared to the previous lead oxadiazole 
8 and the standards vancomycin and linezolid (Table 2). 
Oxadiazole 72c showed better activity against MRSA strains 
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NRS70, VRS1, and VRS2, and S. haemolyticus, B. cereus, B. 
licheniformis, and E. faecalis ATCC 29212 than oxadiazole 8. 
Table 2. Activity of oxadiazoles against Gram-positive organisms. MIC in µg/mL.
Organism 72c 8 vancomycin linezolid
S. aureus ATCC 29213a 1–2 4 1 2
S. aureus ATCC 27660 b 2–4 4 2 1
S. aureus N315 (NRS70)b 1 2 1 1
S. aureus NRS100 (COL)b 2 2 2 1
S. aureus NRS119c 1–2 2 1 32
S. aureus NRS120c 2 2 1 32
S. aureus VRS1d 1 2 64 1
S. aureus VRS2e 1 2 32 1
S. epidermidis ATCC 35547 1 2 4 0.5
S. haemolyticus ATCC 29970 2 4–8 4 1
B. cereus ATCC 13061 4 16 1 0.5
B. licheniformis ATCC 12759 2 8 0.5 0.5
E. faecalis ATCC 29212a 4 8 2 1
E. faecalis 201 (Van S)f 4 4 1 1
E. faecalis 99 (Van R)g 4 4 128 1
E. faecium 119-39A (Van S)f 1 1 0.5 1
E. faecium 106 (Van R)g 1 2 128 1
E. faecium NCTC 7171 1 2 0.5 1
aA quality-control strain to monitor accuracy of MIC testing; bmecA positive, resistant to methicillin, oxacillin, 
and tetracycline; susceptible to vancomycin and linezolid; cmecA positive, resistant to ciprofloxacin, gentamicin, 
oxacillin, penicillin, and linezolid; dvancomycin-resistant MRSA (vanA) clinical isolate from Michigan; 
evancomycin-resistant MRSA (vanA) clinical isolate from Pennsylvania; fvancomycin-susceptible clinical isolate; 
gvancomycin-resistant clinical isolate.
A PK study was conducted with 72c after intravenous (iv) and oral 
(po) administration (Figure 4). Oxadiazole 72c had low clearance 
of 7.8 mL/min/kg, a large volume of distribution of 14.2 L/kg, and 
a long terminal half-life of 21.1 h after iv administration (Table 3). 
Maximum concentration of 1.0 µg/mL was achieved at 2.5 h and 
oral bioavailability was 41%. Systemic exposure and oral 
bioavailability for 72c were generally lower than the corresponding 
parameters for oxadiazole 8. In addition, the half-life for 
distribution after iv administration for oxadiazole 8 was shorter 
than that for 72c.
Figure 4. Pharmacokinetics of 72c after single iv and po 
administration at 20 mg/kg to mice (n=3 mice per time point).
Table 3. Pharmacokinetic parameters of 72c in mice
72c 8a




AUC0–∞ (µM∙min/mL) 2570 3520
CL (ml/min/kg) 7.8 5.7
Vd (L/kg) 14.2 4.7
t1/2 dist (h) 0.4 0.009
t1/2 elim (h) 21.1 9.6




AUC0–∞ (µM∙min/mL) 1040 4060
Cmax (µg/mL) 1.0 2.3
Tmax (h) 2.5 6
t1/2 abs (h) 1.3 0.8
t1/2 dist (h) 6.2 15.9
t1/2 elim (h) 17.0 18.6
F (%) 41 97
aData from Spink et al., reproduced for comparison
Oxadiazole 72c was evaluated in the mouse peritonitis 
MRSA model of infection. The compound showed efficacy, 
with half of the mice surviving after two 20 mg/kg doses of the 
compound given iv at 30 min and 7.5 h after infection. 
Compound 72c was further evaluated in a mouse neutropenic 
thigh MRSA infection model using linezolid-sensitive (NRS70) 
and linezolid-resistant (NRS119) MRSA strains (Figure 5). The 
efficacy of 72c after a single oral dose at 40 mg/kg was 
comparable to that of compound 8, with 1.1-log and 1.5-log 
reduction in bacterial count compared to vehicle in the NRS70 
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and NRS119 strains, respectively. In the NRS119 study, 
bacterial counts after treatment with 72c and 8 were 
significantly lower (p < 0.05) than in the linezolid group. Drug 
concentrations at 48 h after a single oral 40 mg/kg dose of 
compound 8 were 7.6 ± 2.3 µg/g and 6.0 ± 1.2 µg/g in the 
NRS70 and NRS119 uninfected thighs, respectively (Table S5), 
which corresponded to 3- to 4-fold above MIC. Likewise, levels 
of compound 72c were 5.8 ± 1.4 µg/g and 6.4 ± 1.3 µg/g in the 
NRS70 and NRS119 uninfected thighs, respectively (Table S5), 
6-fold above MIC. The levels of linezolid had dropped 
significantly and could not be quantified in the uninfected 
thighs. In summary, 72c showed potent in vitro activity against 
MRSA, oral bioavailability, and efficacy in mouse models of 
MRSA infection. 
Figure 5. Efficacy of 72c in a mouse neutropenic thigh MRSA 
infection model using (a) NRS70 (linezolid-sensitive) and (b) 
NRS119 (linezolid-resistant). Mice (n = 8 per group) were 
made neutropenic by administration of cyclophosphamide. 
Bacteria (105 cfu) were injected intramuscularly into the right 
thigh. A single 40 mg/kg oral dose of vehicle, 72c, 8, or 
linezolid was given 1 h after infection. The thighs were 
harvested 48 h after infection, homogenized, and plated for 
colony counts. Mean ± SEM, *p < 0.05, **p<0.01, ***p<0.001 
by Mann-Whitney U test two-paired. 
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